TERT-induced adoptive T cell therapy - Eutilex

Drug Profile

TERT-induced adoptive T cell therapy - Eutilex

Alternative Names: Telomerase reverse transcriptase-induced natural T cell therapy - Eutilex; TERT 4-1BB CTL - Eutilex; TERT-induced natural T cell therapy - Eutilex; TERTiNT - Eutilex

Latest Information Update: 14 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Eutilex
  • Class Antineoplastics; T lymphocyte cell therapies
  • Mechanism of Action CD8 positive T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Cancer

Most Recent Events

  • 06 Nov 2017 Phase-I/II clinical trials in Cancer in South Korea (Parenteral) before November 2017 (Eutilex pipeline, November 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top